Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Key event: the FDA will decide on Summit Therapeutics' ivonescimab by Nov. 14 and the drug’s lack of a statistically significant overall survival benefit outside China raises a high risk of rejection that could drive a >20% share drop. Axsome reported 2025 revenue of $638.5M (+65.5% YoY) and awaits potential AXS‑05 approval for Alzheimer's agitation by end‑April, while Madrigal posted 2025 revenue of $958.4M (+432% YoY) from Rezdiffra and continues to expand its MASH pipeline. Market caps cited: Axsome $8.1B and Madrigal $10.2B; the piece suggests these catalysts could meaningfully re‑rate individual stocks, with Summit facing binary regulatory upside/downside.

Analysis

The market is treating Summit as a binary regulatory bet, but the deeper value swing comes from how payers and oncologists would reprice an approved entrant into a crowded immuno-oncology mix. If approved, uptake will be driven less by headline efficacy and more by label differentiation, diagnostic-guided prescribing, and contracting dynamics with large oncology centers — meaning revenue realization will be uneven across regions and take multiple quarters to manifest. Conversely, a negative outcome will not only compress Summit equity but could reset investor appetite for similar mid‑stage immuno-oncology names, amplifying sectorwide derisking beyond the single-company shock.

Axsome and Madrigal are on a different axis: one is executing a scaled commercial rollout and awaiting label expansion that would leverage existing sales channels; the other is extending a high‑value niche franchise where uptake is cadence‑driven by guidelines and specialist adoption. Execution and supply chain (manufacturing fill/finish, specialty pharmacy logistics) are near-term gating items that can flip strong revenue prints into multiple-bagger sentiment or vice versa. Watch options flow and inventory turns at specialty distributors as early indicators of organic uptake versus promotional push.

From a risk-timing perspective, treat Summit as a short-duration binary with elevated vega: position sizing should reflect a >50% implied move on event volatility rather than fundamentals. For Axsome and Madrigal, skew favors owning optionality through asymmetric instruments (calendar or vertical call spreads) to capture discrete regulatory/commercial catalysts while capping premium decay. The consensus underweights the operational cliff risk in commercial-stage names; a “safe” revenue print can still disappoint if gross-to-net and rebates accelerate as payers push back on list price dynamics.

Key Decisions for Investors

• Tactical hedge on SMMT: initiate a 3–6 month put-spread (buy 1 30–40% OTM put, sell 1 deeper OTM put) sized at 2–4% of portfolio to capture a >2x payoff on a negative regulatory outcome while capping premium paid — delta-hedge if implied vol spikes pre-decision.
• Paired risk-off trade: short SMMT equity (or buy puts) and simultaneously go long AXSM via a 6–12 month call‑spread (buy 1 25–35% OTM call, sell 1 60–80% OTM call) to express a view that execution/label expansion in Axsome will outpace Summit’s binary outcome; size 1:0.5 (short:long) to limit net exposure.
• Convex long on MDGL: buy 12–24 month LEAP calls or a debit call‑spread 20–30% OTM to capture guideline adoption and continued specialty pricing power; cap premium by using spreads and limit allocation to 2–5% of risk capital given commercial execution and competitive risks.
• Event volatility play: if implied volatility for SMMT spikes >40% relative to AXSM/MDGL, sell a small portion of near-term call skew and rotate into longer-dated calls on MDGL to monetize overpriced vega and redeploy into secular growth optionality, keeping net vega exposure neutral.